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Hepatic lipase mutation may reduce vascular disease preva-
lence in hemodialysis patients with high CETP levels.
Background. Uremic dyslipidemia characterized by reduced
high-density lipoprotein (HDL) cholesterol levels is one of
the major contributors to the high incidence of cardiovascular
disease in hemodialysis patients. Hepatic lipase (HL), together
with cholesteryl ester transfer protein (CETP), may not only
promote reverse cholesterol transport but also enhance pro-
duction of small, dense, more atherogenic low-density lipopro-
tein (LDL). A common C-514T mutation of the promoter
region of the HL gene reportedly increases HDL cholesterol
levels. However, whether the HL mutation is antiatherogenic
or proatherogenic has remained unknown in uremic patients
and the general population.
Methods. We investigated the influence of the mutation and
its interaction with CETP on HDL cholesterol levels and the
apparent atherosclerotic complications in 183 hemodialysis pa-
tients aged over 30 years who had received no antilipemic
drugs.
Results. In patients with CETP levels 2.2 g/mL [high
CETP (HCT) group, N  97], subjects with the TT genotype
had a significantly higher level of HDL cholesterol than those
without TT genotype (56.8 15.9 mg/dL vs. 45.7 13.4 mg/dL,
P  0.001), but not in patients with CETP levels 2.2 g/mL
[low CETP (LCT) group]. Multiple linear regression analysis
showed that the TT genotype was a major independent positive
determinant for HDL cholesterol levels in the HCT not LCT
group. Among the HCT group patients, subjects with the TT
genotype (N  25) had a tendency toward lower prevalence
of vascular disease than those without TT genotype (N  72)
(4.0% vs. 22.2%, P  0.07). In this subgroup, TT genotype
had an independent odds ratio of 0.041 (95% CI 0.002 to 0.75,
P  0.05) after adjusting for other risk factors.
Conclusion. The TT genotype of HL mutation may serve
as a protective factor against vascular disease by increasing
HDL cholesterol levels in hemodialysis patients with higher
CETP levels.
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environment interaction, uremic dyslipidemia.
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The high incidence of atherosclerotic complications is
frequently found in patients undergoing maintenance
dialysis [1]. Uremic dyslipidemia has been considered a
major cause of susceptibility to atherosclerosis in this
setting [2, 3], although other factors such as increased
oxidant stress, hyperhomocysteinemia, and disorders of
calcium and phosphorus metabolism have been sug-
gested [4, 5]. The impaired lipid metabolism is character-
ized mainly by decreased serum levels of high-density
lipoprotein (HDL) cholesterol and decreased reverse
cholesterol transport, which result from reduced activity
of lipoprotein lipases and lecithin-cholesterol acyltrans-
ferase [6].
Hepatic lipase (HL), a 65 kD glycoprotein synthesized
and distributed in the liver, catalyses the hydrolysis of
triglyceride in native lipoproteins [7]. HL can promote
reverse cholesterol transport by converting larger HDL
particles back to smaller ones with greater antiathero-
genic effects [7, 8], while it not only may decrease HDL
cholesterol levels but also may produce low-density lipo-
protein (LDL) particles with smaller and denser nature
that are more atherogenic [7, 9, 10]. At present, these
multiple roles of HL in lipoprotein metabolism make it
difficult to determine whether HL action is antiathero-
genic or proatherogenic [7]. Indeed, clinical findings on
HL-deficient patients were less clear on the impact of HL
on atherosclerosis development [7]. Recently, a C- to-T
mutation at position -514 (C-514T mutation) of the HL
promoter has been identified and shown to be associated
with lowered HL activity and elevated HDL cholesterol
levels [9, 11]. In several studies, this HL-deficient muta-
tion has not been consistently linked with a risk of coro-
nary heart disease [9, 12, 13].
Cholesteryl ester transfer protein (CETP) can transfer
cholesteryl ester (CE) from large CE-rich HDL to very
LDL in exchange for triglyceride [8, 14]. This process
favors hepatic uptake of CE in HDL and formation of
pre- HDL particles with a high likelihood for cellular
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cholesterol efflux, promoting reverse cholesterol trans-
port [8, 14, 15]. However, an elevation in serum CETP
leads to reduced HDL cholesterol levels and increased
LDL cholesterol levels [16]. As for the general popula-
tion, several studies have reported that CETP was pro-
atherogenic [17, 18], while other studies have reported
that the protein was antiatherogenic [19, 20]. Therefore,
the role of CETP in atherosclerosis is not clearly defined.
In a large number of hemodialysis patients, we recently
reported that high CETP and high HDL cholesterol sta-
tus serves as a protective factor against vascular disease
[21], while low CETP and low HDL cholesterol status
is a risk factor for the disease [22]. These findings suggest
that the antiatherogenic effects of CETP may be accentu-
ated in dialysis patients.
HL together with CETP may further promote reverse
cholesterol transport via enhancing hepatic uptake of CE
in HDL and formation of small HDL particles [23–25],
although the cooperation also may produce small dense,
more atherogenic LDL particles [10, 16, 26] and may
further decrease HDL cholesterol levels [7, 16]. Consid-
ering that uremic patients frequently have a decrease
in both HDL cholesterol levels and reverse cholesterol
transport activity [6] and an increase in atherogenic small
LDL particles [27], it appears very important to clarify
the impacts of HL and its interaction with CETP on
atherosclerosis in patients with end-stage renal disease
(ESRD). However, there have been no studies investi-
gating whether the HL-deficient C-514T mutation is anti-
or proatherogenic in patients receiving dialysis treat-
ment. Furthermore, no information has been collected
about the effect of the HL mutation on HDL cholesterol
levels in this setting. The present study examined, for
the first time, the HL C-514T mutation and its interaction
with CETP in relation to atherosclerotic complications
in uremic patients. We also identified the homozygote
for the HL mutation as a major determinant of HDL
cholesterol levels, especially in the hemodialysis patients
with high CETP status.
METHODS
Subjects
Between September 1998 and March 1999, we investi-
gated a total of 183 hemodialysis patients aged 30 to 84
years at the dialysis centers in the Fukui and Niigata
prefectures. Hemodialysis had been initiated because of
ESRD due to chronic glomerulonephritis (N  100),
diabetic nephropathy (N 33), polycystic kidney disease
(N  8), nephrosclerosis (N 12), chronic pyelonephri-
tis (N  13), toxemia of pregnancy (N  1), a urogenital
malformation (N  1), miscellaneous nephropathies
(N 4), and shrunken kidney of unknown etiology (N
11). Patients were undergoing three times a week 3- to
5-hour hemodialysis sessions, generally using high-flux
membranes and standard heparin doses. The mean Kt/V
urea was 1.31 0.25. The mean length of time on hemo-
dialysis was 7.0  7.0 years. Informed consent for study
participation was obtained from each subject. Smoking
was defined on the basis of current cigarette smoking or
previous habitual smoking. Hypertension was defined as
a systolic blood pressure 140 mm Hg or a diastolic
pressure 90 mm Hg, or the use of antihypertensive
drugs. Dietary instructions included daily intake of 30
to 35 kcal/kg and 1.2 g protein/kg and the general sugges-
tion of intake of 55% to 60% carbohydrate, 25% fat,
and 15% to 20% protein.
Biochemical assays
Venous blood samples (serum and whole blood) were
collected immediately prior to dialysis 2 hours after
breakfast or 2 to 3 hours after lunch from all dialysis
patients in September 1998. Serum levels of total choles-
terol (TC) and triglyceride (TG) were measured by a
standard enzymatic method. HDL cholesterol levels
were measured in the supernatant after precipitation
of other lipoprotein fractions with phosphotungstic acid
[28]. Serum albumin levels were determined by the bro-
mocresol green dye-binding assay. Serum CETP concen-
trations were measured using an enzyme-linked immu-
nosorbent assay (ELISA) with monoclonal antibodies
(BML, Saitama, Japan). The intra- and interassay coef-
ficients of variation were 2.6% and 5.2%, respectively.
We measured postprandial serum levels of lipids and
proteins for the following reasons: (1) it was very difficult
to collect fasting blood samples from all patients because,
in our dialysis centers, about half of the patients receive
hemodialysis treatment during the afternoon; (2) it was
reported in healthy subjects that total cholesterol levels
were unchanged and HDL cholesterol levels did not
change much (less than 10%) after a meal [29]; and (3)
no significant difference between serum CETP levels
during a fast and 2 hours after a meal in healthy subjects
(N  12) was observed in our laboratory (2.44  0.16
g/mL vs. 2.40  0.18 g/mL, NS).
Assessment of vascular disease
Coronary artery disease. Coronary artery disease was
established from a review of medical records. A previous
myocardial infarction was defined by a physician’s diag-
nosis based on chest pain, confirmatory electrocardio-
graphic changes, and enzyme determinations or findings
from coronary angiography. Angina pectoris was diag-
nosed when a stress test was positive and/or coronary
artery stenosis (75% of luminal diameter) was demon-
strated by angiography. Patients with a history of myo-
cardial infarction or angina pectoris were classified as
having coronary artery disease.
Peripheral vascular disease. Peripheral vascular dis-
ease was diagnosed by diminished pulses on the patient
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history and clinical examinations. Symptoms of intermit-
tent claudication were recorded by a physician. The pres-
ence of clinical signs of peripheral vascular disease were
determined by a physical examination, including palpa-
tion of pulses and auscultation of bruits at the arteries
of lower extremities. In the patients with clinical signs,
the ankle and arm systolic blood pressures were mea-
sured. An ankle/arm index0.95 indicated the presence
of peripheral vascular disease. In the patients with both
an index 0.95 and clinical signs, including intermittent
claudication, angiography was performed. When periph-
eral artery stenosis (75% of luminal diameter) was
found, the patients were diagnosed as having peripheral
vascular disease.
Cerebral vascular disease. Cerebral vascular disease
was defined as a stroke or transient ischemic attack [i.e.,
functional deficit for at least 24 hours and positive find-
ings on computed tomography (presence of hypodensity
area) or magnetic resonance imaging (simultaneous
presence of hypointensity area on T1-weighted image
and hyperintensity area on T2-weighted image), or an
acute functional deficit lasting for 24 hours or less], re-
spectively. Patients with cerebral or subarachinoid hem-
orrhage were excluded.
A patient was considered as having a vascular disease
when at least one of these three defined vascular diseases
was found.
Determination of the C-514T mutation in
the HL gene
Genomic DNA was extracted from peripheral blood
leukocytes using a commercial apparatus (MFX-2000)
(Toyobo Tsuruga, Fukui, Japan) and a commercially
available kit (MagExtractor–Genome) (Toyobo Tsur-
uga). Identification of the C-514T mutation in the HL
gene was performed by polymerase chain reaction (PCR)
using a pair of primers as described by Guerra et al [11].
Ten microliters of the 300 bp PCR product was subjected
to Nla III digestion (10 U in a 15 L digest) at 37C
for 3 hours. The digests were electrophoresed on 1.2%
agarose gels.
Statistical analysis
Continuous variables are expressed as means  SD.
Differences in continuous variables between patients
with and without vascular disease and among three geno-
type groups were assessed by a nonparametric test (Mann-
Whitney U test) and analysis of variance (ANOVA) with
multiple comparisons, respectively. Chi-square analysis
was used to assess differences in noncontinuous variables
between patients with and without vascular disease or
among patients with differing genotypes. Multiple linear
regression analysis was performed to determine the inde-
pendent predictors of serum HDL cholesterol levels.
Multivariate logistic regression analysis was used to as-
Table 1. Characteristics of hemodialysis patients
All patients (N  183)
Age years 58.912.5
Gender male/female 107/76
Hemodialysis duration years 7.07.0
Serum cholesterol mg/dL 15633
Triglyceride mg/dL 9750
HDL-cholesterol mg/dL 4918
Serum albumin g/dL 3.70.4
CETP lg/mL 2.20.6
Hypertension (%) 163 (89.1)
Diabetes mellitus (%) 33 (18.0)
Smoking history (%) 79 (43.2)
Vascular disease (%) 38 (20.8)
CETP is cholesteryl ester transfer protein; HLD is high-density lipoprotein.
sess the independent contribution of clinical variables
including CETP levels and the C-514T mutation in the
HL gene to apparent vascular disease in dialysis patients.
A level of P  0.05 (two-tailed tests) was considered
statistically significant. All statistical analyses were per-
formed using the SPSS statistical software package
(SPSS, Inc., Chicago, IL, USA).
RESULTS
Table 1 shows clinical and laboratory characteristics
of hemodialysis patients. The means of HDL cholesterol
and CETP levels were 49  18 mg/dL and 2.2  0.6
g/mL, respectively. Among a total of 183 hemodialysis
patients, 50 subjects were homozygous for the HL C/T
mutation (TT genotype), 79 subjects were heterozygous
for the mutation (CT genotype), and 54 subjects were
the wild-type (CC genotype) as shown in Table 2. The
frequency of C and T alleles were 51.1% and 48.9%,
respectively. The distribution of HL genotypes agreed
with the Hardy-Weinberg equilibrium. No significant dif-
ferences among the three genotypes were found in any
clinical or laboratory characteristics (Table 2). When
patients with the CT genotype and those with the CC
genotype were analyzed as a single group (those without
TT genotype), patients with the TT genotype showed a
significantly higher serum level of HDL cholesterol than
those without TT genotype (52  18 mg/dL vs. 47  18
mg/dL, P  0.05) (Table 2).
Considering that CETP may influence HDL choles-
terol levels, all the patients were divided into four groups
according to quartile of CETP concentrations, and HDL
cholesterol levels were compared among the CETP sub-
groups. HDL cholesterol levels were higher in patients
with the TT genotype than in those with the CT or the
CC genotype for the upper two quartiles: for the highest
quartile of CETP (N  47) (CETP  2.6 g/mL, 63 
14 mg/dL vs. 51  15 mg/dL vs. 45  14 mg/dL, P 
0.02) and for the second (N  50) (CETP 2.6 g/mL 
CETP 2.2 g/mL, 52 16 mg/dL vs. 45 13 mg/dL vs.
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Table 2. Characteristics in relation to the hepatic lipase (HL) genotypes
Non-TT genotypes (N  133)
TT genotype (N  50) CT genotype (N  79) CC genotype (N  54)
Age years 59.313.5 59.512.3 57.612.0
Gender male/female 28/22 47/32 32/22
Hemodialysis duration years 5.56.5a 6.97.4 8.46.8
Serum albumin g/dL 3.60.4 3.70.3 3.60.5
Serum cholesterol mg/dL 15935 15635 15129
Triglyceride mg/dL 9861 9948 9342
HDL-C mg/dL 5218b 4819 4615
CETP lg/mL 2.20.6 2.20.6 2.30.6
Hypertension (%) 43 (86.0) 70 (88.6) 50 (92.5)
Diabetes mellitus (%) 13 (26.0)c 13 (16.5) 7 (13.0)
Smoking history (%) 22 (44.0) 37 (46.8) 20 (37.0)
Vascular disease (%) 6 (12.0)c 17 (21.5) 15 (27.8)
CETP is cholesteryl ester transfer protein; HLD is high-density lipoprotein.
aP  0.1 non-TT genotype by Mann-Whitney U test
bP  0.05 non-TT genotype by Mann-Whitney U test
cP  0.1 non-TT genotype by chi-square analysis
41  10 mg/dL, P  0.1), while there were no significant
differences in HDL cholesterol levels among the geno-
types for the lower two quartiles: for the third (N  46)
(CETP 2.2 g/mL CETP 1.8 g/mL, 52 24 mg/dL
vs. 45  13 mg/dL vs. 51  23 mg/dL, NS) and for the
lowest (N  40) (CETP  1.8 g/mL, 43  12 mg/dL
vs. 48  23 mg/dL vs. 48  12 mg/dL, NS). Therefore,
we selected the median value (2.2 g/mL) of CETP con-
centrations as a dividing line to define the high and low
CETP subgroups. In the high CETP (2.2 g/mL) sub-
group (N  97), patients with the TT genotype showed
a significantly higher serum level of HDL cholesterol
than those with the CT genotype and those with the CC
genotype (Fig. 1A) and than those without TT genotype
(57  16 mg/dL vs. 46  13 mg/dL, P  0.001), while
in the low CETP ( 2.2 g/mL) subgroup (N  86),
the HDL cholesterol levels were similar in patients with
differing HL genotypes (Fig. 1B). Multiple linear regres-
sion analysis in all the patients identified female gender
and TT genotype as positive determinants and triglycer-
ide as a major negative determinant of HDL cholesterol
levels (Table 3). In the high CETP subgroup, the TT
genotype was a major independent determinant of HDL
cholesterol levels after adjustment for all the other clini-
cal variables, including triglyceride (Table 4), while in
the low CETP subgroup, it showed no independent asso-
ciation with HDL cholesterol levels (data not shown).
Next, we examined the effects of the HL TT genotype
on the prevalence of apparent vascular disease in hemo-
dialysis patients. Of all the patients (N  183), a total
of 38 subjects (20.8%) had apparent vascular disease.
Coronary artery disease, peripheral vascular disease, and
cerebral vascular disease were identified in 17, 4, and 24
patients, respectively. As shown in Table 5, patients with
vascular disease were older and had a shorter duration
of hemodialysis, lower serum levels of HDL cholesterol
Fig. 1. High-density lipoprotein (HDL) cholesterol levels according to
the hepatic lipase (HL) genotypes among patients taking no antilipemic
drugs. (A ) In patients with cholesteryl ester transfer proteins (CETP)
levels 2.2 g/mL (N  97), those with the TT genotype had a signifi-
cantly higher level of HDL cholesterol than those with the CT and
those with the CC genotype (56.8  15.9 mg/dL vs. 48.0  14.1 mg/dL
vs. 42.6  12.0 mg/dL, P  0.005). (B ) In patients with CETP levels
2.2 g/mL (N  86), those with differing genotypes did not differ in
HDL cholesterol levels.
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Table 3. Multiple regression analysis of variables affecting
serum high-density lipoprotein (HDL) cholesterol levels
in hemodialysis patientsa
Standard regression
Variables coefficients P value
Age years 	0.041 0.3273
Gender (male  0, female  1) 0.164 0.0308
Diabetes mellitus (presence  1,
absence  0) 	0.183 0.0100
Smoking (presence  1, absence  0) 	0.029 0.7027
Hemodialysis duration years 0.018 0.8033
Triglyceride mg/dL 	0.380 0.001
Serum albumin g/dL 0.039 0.5827
CETP lg/mL 	0.041 0.5569
HL genotypes (CC, CT  0, TT  1) 0.155 0.0219
R 2 0.252 0.001
CETP is cholesteryl ester transfer protein.
a R 2 is mulitple coefficient of determination
and albumin, and a higher prevalence of diabetes melli-
tus than those without vascular disease. Patients with the
TT genotype had a tendency toward lower prevalence of
vascular disease than those without TT genotype for the
entire group (12.0% vs. 24.1%, P  0.1) (Table 2) and
for the high CETP subgroup (4.0% vs. 22.2%, P  0.07)
(Fig. 2A), while for the low CETP subgroup, prevalences
of vascular disease were similar in patients with and
without TT genotype (Fig. 2B).
In addition to HDL cholesterol levels, patients with
and without TT genotype differed in some other charac-
teristics (Tables 2 and 6). As for the entire group, patients
with the TT genotype had a tendency toward shorter
duration of hemodialysis and higher prevalence of diabe-
tes mellitus than those without TT genotype (Table 2).
As for the high CETP subgroup, patients with the TT
genotype had a significantly higher level of total choles-
terol than those without TT genotype (Table 6). There-
fore, we finally investigated the independent influences
of the TT genotype on vascular disease in hemodialysis
patients using multiple logistic regression analysis in a
model, including age (years), gender, duration of hemo-
dialysis (years), total cholesterol (mg/dL), serum albu-
min (g/dL), HDL cholesterol (mg/dL), CETP (g/mL),
as well as the presence or absence of hypertension, diabe-
tes mellitus, smoking history, and TT genotype in the
HL gene. Multivariate analysis in the entire group identi-
fied the TT genotype [odds ratio (OR), 0.19; 95% confi-
dence interval (95% CI), 0.06 to 0.62; P  0.01] as sig-
nificant independent predictors for vascular disease
(Table 7). In the high CETP subgroup, the TT genotype
was again selected as a significant predictor [OR, 0.041
(95% CI, 0.002 to 0.75; P  0.05)] after adjustment for
other risk factors, while in the low CETP subgroup the
TT genotype was not an independent predictor for vascu-
lar disease (Table 7).
Table 4. Multiple regression analysis of variables affecting a
serum high-density lipoprotein (HDL) cholesterol levels
in hemodialysis patients with cholesteryl ester transfer
protein (CETP) levels 2.2 g/mLa
Standard regression
Variables coefficients P value
Age years 	0.167 0.0770
Gender (male  0, female  1) 0.200 0.0456
Diabetes mellitus (presence  1,
absence  0) 	0.157 0.0763
Smoking (presence  1, absence  0) 	0.175 0.0810
Hemodialysis duration years 	0.092 0.3177
Triglyceride mg/dL 	0.364 0.001
Serum albumin g/dL 0.140 0.1159
HL genotypes (CC, CT  0, TT  1) 0.342 0.001
R 2 0.435 0.001
a R 2 is mulitple coefficient of determination
DISCUSSION
We studied for the first time the HL C-514T mutation
in uremic patients on maintenance hemodialysis. The
frequency of the mutant allele in the present Japanese
patients (T allele, 48.9%) was similar to that recently
reported for the general population of Japanese males
[30] and our preliminary findings for Japanese healthy
subjects (49.1%, other detailed data not shown) and was
about threefold higher than those previously reported
for American and European general populations [9].
One of the most notable observations from the present
study is that the TT genotype for HL C-514T mutation
is a major positive determinant for HDL cholesterol
levels in hemodialysis patients with high CETP levels
(2.2 g/mL) but not in those with low CETP levels
(2.2 g/mL). Since HL readily hydrolyzes TG in large
TG-rich HDL and then increases the HDL clearance
rate from the blood stream by enhancing not only hepatic
uptake of large HDL particles but also conversion of
larger TG-rich HDL ones to smaller HDL ones [7, 9,
24], low HL activity results in increased HDL cholesterol
levels [7, 9]. Recently, the HL C-514T mutation was
reported to be associated with reduced HL activity and
to cause increased HDL cholesterol levels, which was
also supported by our study, especially large TG-rich
HDL particles [9, 11]. Subjects with the TT genotype
have lower HL activity and higher HDL cholesterol lev-
els than those with a non-TT genotype [9, 11]. Since
CETP preferably forms the large TG-rich HDL from
the large CE-rich one via exchange of CE for TG [14, 16]
and also elevates serum lecithin:cholesterol acytransfer-
ase (LCAT) activity [31], the production rate of large
TG-rich HDL is necessarily higher in high CETP status
than in low CETP status. Considering that the large TG-
rich HDL is a better substrate for HL [7], in the high
CETP subgroup where TG-rich HDL is abundant, pa-
tients with a non-TT genotype may have higher HDL
clearance than those with the TT genotype, while in the
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Table 5. Characterisitcs of hemodialysis patients with and without vascular disease (VD)a
All patients (N  183) Patients with CETP levels 2.2 g/mL (N 97)
VD (
) (N  38) VD (	) (N  145) VD (
) (N  17) VD (	) (N  80)
Age years 68.110.7b 56.511.9 69.212.6b 56.911.5
Gender male/female 24/14 83/62 9/8 41/39
Hemodialysis duration years 3.34.3b 7.97.3 2.62.9b 9.07.7
Serum cholesterol mg/dL 15736 15533 16130 15831
Triglyceride mg/dL 11063 9446 9842 9341
HDL-cholesterol mg/dL 4215b 5019 4010c 5015
Serum albumin g/dL 3.60.4c 3.70.4 3.60.3c 3.70.4
CETP lg/mL 2.10.5 2.30.6 2.50.3 2.70.5
Hypertension (%) 36 (94.7) 127 (87.6) 16 (94.1) 70 (87.5)
Diabetes mellitus (%) 13 (34.2)b 20 (13.8) 6 (35.3)c 9 (11.3)
Smoking history (%) 15 (39.5) 64 (44.4) 6 (35.3) 37 (46.2)
HDL is high density lipoprotein; CETP is cholesteryl ester transfer protein.
a VD (
) and VD (	) indicate patients with and without vascular disease, respectively. Differences in continuous and categoric variables between VD (
) and
VD (	) were assessed by Mann-Whitney U test and by chi-square analysis or Fisher’s exact probability test, respectively
b P  0.01 vs. VD (	) in each patient group; c P  0.05, vs. VD (	) in each patient subgroup
Fig. 2. Vascular disease prevalence according to the hepatic lipase
(HL) genotype. The non-TT genotypes include both the CC and CT ge-
notypes. (A ) In patients with cholesteryl ester transfer proteins (CETP)
levels 2.2 g/mL (N  97), those with TT genotype had a tendency
toward lower prevalence of vascular disease than those with a non-TT
genotype (4.0% vs. 22.2%, P  0.07). (B ) In patients with CETP levels
2.2 g/mL (N 86), there was a similar prevalence of vascular disease
in the TT and non-TT genotypes (20.0% vs. 26.2%, NS).
Table 6. Characteristics of patients with TT or non-TT genotypes
in a high cholesteryl ester transfer protein (CETP) subgroupa
TT genotype Non-TT genotypes
(N  25) (N  72)
Age years 60.211.9 58.612.8
Gender male/female 15/10 35/37
Hemodialysis duration years 6.87.4 8.27.5
Serum albumin g/dL 3.60.4 3.60.4
Serum cholesterol mg/dL 16932b 15529
Triglyceride mg/dL 8529 9744
HDL-cholesterol mg/dL 5716c 4613
CETP lg/mL 2.60.4 2.70.5
Hypertension (%) 21 (84.0) 65 (90.3)
Diabetes mellitus (%) 4 (16.0) 11 (15.3)
Smoking history (%) 14 (56.0) 29 (40.3)
Vascular disease (%) 1 (4.0)d 16 (22.2)
HDL is high-density lipoprotein.
a Non-TT genotypes include both CT genotype and CC genotype. A high
CETP subgroup includes patients with CETP levels 2.2 g/mL
b P  0.05 non-TT genotypes by MannnWhiteny U-test
c P  0.01 non-TT genotypes by Mann-Whitney U-test
d P  0.07 non-TT genotypes by Fisher’s exact probability test
low CETP subgroup where TG-rich HDL is less, the HL-
mediated HDL clearance may be similar among subjects
with differing HL genotypes. Consequently, the HDL-
raising effect of the TT genotype may be more conspicu-
ous in the high CETP subgroup than in the low CETP
one. At present, however, the presence of the interaction
between the HL mutation and CETP antigen in the gen-
eral population and the precise mechanism remains to
be clarified.
Another notable finding in the present study was that
the TT genotype in the HL mutation was an independent
protective factor against vascular disease in the high
CETP subgroup but not in the low CETP subgroup. It
is highly likely that this antiatherogenic effect of the
TT genotype arises mainly from its association with the
marked increase in HDL cholesterol levels (Fig. 1A). In
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Table 7. Multiple logistic regression analysis of the influence of selected variables on apparent vascular disease in hemodialysis patientsa
Variables Regression coefficient SE Odds ratio (95% CI) P value
All patientsb
Age 0.090 0.023 1.09 (1.05–1.14) 0.001
HL TT genotype 	1.657 0.605 0.19 (0.06–0.62) 0.01
Diabetes mellitus 1.386 0.566 4.00 (1.32–12.13) 0.05
HDL cholesterol 	0.032 0.016 0.97 (0.94–0.99) 0.05
Patients with CETP 2.2 g/mLc
HL TT genotype 	3.190 1.483 0.041 (0.002–0.75) 0.05
Age 0.065 0.034 1.07 (1.00–1.14) 0.056
Duration of hemodialysis 	0.174 0.092 0.83 (0.69–1.00) 0.059
Patients with CETP 2.2 g/mLc
Age 0.122 0.037 1.13 (1.05–1.21) 0.001
Diabetes mellitus 1.463 0.806 4.32 (0.89–21.10) 0.069
HDL is high-density lipoprotein; CETP is cholesterol ester transfer protein.
a Variables with P values less than 0.1 are listed
b Variables are age (years), gender (female  0, male  1), duration of hemodialysis (years), serum cholesterol (mg/dL), serum albumin (g/dL), HDL-cholesterol
(mg/dL), CETP (g/mL), and absence (0) or presence (1) of hypertension, diabetes mellitus, history of smoking, and HL TT genotype
c Variables are all those used for analysis of all patients except for CETP (g/mL)
general, increased HDL cholesterol levels have been
recognized as a protective factor against atherosclerotic
complications in uremic patients [22, 32–34] as well as
general populations [35–37]. In our study, considering
all the patients, HDL cholesterol (mg/dL) was signifi-
cantly and inversely associated with vascular disease
prevalence after adjustment for all the other clinical vari-
ables including the TT genotype (Table 7), while in the
high CETP subgroup, the TT genotype but not HDL
cholesterol was selected as an independent predictor for
vascular disease. These findings may reflect much
stronger association of the TT genotype with increased
HDL cholesterol levels in high CETP subgroup than in
the entire group. Additionally, considering that for all
the patients the TT genotype has an inverse relationship
with vascular disease prevalence after adjustment for
both CETP and HDL cholesterol concentrations, it
would seem that the HL mutation contributes partially
to vascular disease risk through a certain mechanism
other than its HDL cholesterol increasing effect.
We previously reported that CETP serves as a protec-
tive factor against vascular disease in hemodialysis pa-
tients with normal to high HDL cholesterol levels [21].
As discussed above, HL together with CETP may pro-
mote not only hepatic uptake of HDL cholesterol but
also conversion of larger HDL particles to smaller ones
with greater potential for cellular cholesterol efflux, lead-
ing to increased reverse cholesterol transport activity [7,
8, 23, 24]. Thus, it was at first suggested that simultaneous
elevation of both CETP and HL would be a more protec-
tive factor against vascular disease. However, in contrast
to our expectation, we observed in the current study that
hemodialysis patients with high CETP levels and the TT
genotype leading to the lowest HL activity had the lowest
prevalence of vascular disease. This suggests that low
HL activity may be a protective factor against vascular
disease in high CETP status. HL has been shown to have
bidirectional roles on atherosclerosis development [7, 9].
Although HL may promote remnant lipoprotein clear-
ance and reverse cholesterol transport [7, 9], its activity
is inversely correlated with HDL cholesterol levels [7, 9].
Several recent studies have reported that HL in coopera-
tion with CETP may enhance formation of small, dense
LDL, which has more atherogenic potential [10, 16, 26].
Furthermore, low HL activity resulting from the TT ge-
notype for the HL C/T mutation or from drug therapy
with 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors is reportedly associated with more buoyant,
less atherogenic LDL particles [38, 39] and with regres-
sion of coronary heart disease [39]. In uremic patients,
increased serum levels of small dense LDL have been
found and recently recognized as a risk factor for vascu-
lar disease [27, 40, 41]. In the high CETP subgroup,
hemodialysis patients with the TT genotype might have
had lower levels of small dense LDL as well as actually
higher levels of HDL cholesterol than those with a non-
TT genotype, possibly leading to a much lower preva-
lence of vascular disease in the former than in the latter,
although patients with the TT genotype had apparently,
but not significantly, lower postprandial TG levels than
those without TT genotype.
Recently, several studies showed a relationship be-
tween the HL C/T mutation and impaired glucose toler-
ance despite little understanding of the mechanisms
[42, 43]. In our study, patients with the TT genotype
had a higher prevalence of diabetes mellitus than those
without TT genotype with marginal significance for the
whole group (Table 2), with significance for the low
CETP subgroup (36.0% vs. 14.8%, P  0.05) and with
no significance for the high CETP subgroup (Table 6).
Although our these findings supported the association of
the HL mutation with impaired glucose tolerance [42, 43]
and for the first time suggested that the genetic effect
may be modified by CETP status, further examinations
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are needed to clarify the more susceptibility to diabetes
mellitus in individuals with the TT genotype and the
interaction between the HL mutation and CETP antigen.
In our study, most serious limitations are the lack
of fasting samples. To overcome this shortcoming, we
reanalyzed the impact of HL mutation on HDL choles-
terol levels and vascular disease prevalence using other
two data sets of nonfasting lipid levels (total cholesterol,
HDL cholesterol, and TG) measured on previous differ-
ent days (in October 1998 and in November 1998). Con-
sequently, we were again able to obtain results similar
to those shown in Fig. 1 and Tables 2 to 7. Using one set
of lipid data, significant differences in HDL cholesterol
levels between the HL (TT, CT, and CC) genotypes were
found in the highest quartile of CETP (57  9.2 mg/dL
vs. 47  11 mg/dL vs. 41  16 mg/dL, P  0.01) and in
the second (51  13 mg/dL vs. 44  13 mg/dL vs. 40 
18 mg/dL, P  0.05), while the HL genotypes did not
differ in HDL cholesterol levels in the third (51  13
mg/dL vs. 42  13 mg/dL vs. 51  18 mg/dL, NS) and
in the lowest (43  11.2 mg/dL vs. 45  19 mg/dL vs.
43  11 mg/dL, NS). As for another set of lipid data,
significant differences in HDL cholesterol levels between
the genotypes were also found in the highest (58  10
mg/dL vs. 44  12 mg/dL vs. 42  14 mg/dL, P  0.005)
and in the second (50  11 mg/dL vs. 42  11 mg/dL
vs. 39  10 mg/dL, P  0.05), while the genotypes did
not differ in HDL cholesterol levels in the third (48 
16 mg/dL vs. 45  13 mg/dL vs. 51  20 mg/dL, NS)
and in the lowest (42  13 mg/dL vs. 46  16 mg/dL
vs. 41  9.2 mg/dL, NS). Furthermore, multiple linear
regression analyses using these lipid data proved that
the TT genotype was a major positive determinant of
HDL cholesterol levels for all the patients and for the
patients with high CETP but not for those with low
CETP (data not shown). These findings strongly recon-
firmed the reported association of the HL mutation with
HDL cholesterol levels (Fig. 1 and Tables 2 to 4 and 6).
As for the relationship between the HL mutation and
vascular disease prevalence, multiple logistic regression
analyses using these lipid data revealed a significant in-
verse relationship between the HL TT genotype and
vascular disease prevalence for all the patients and for
the patients with high CETP but not for those with low
CETP after adjustment of all the other variables includ-
ing HDL cholesterol and CETP (data not shown), which
was consistent with results shown in Table 7.
Several other limitations exist in the current study.
Only apparent, but not subclinical, vascular disease at
one time point was identified. It would have been prefer-
able to measure fasting lipid levels and to examine HDL
or LDL particle composition, including small dense LDL
particles. Presumed association of the HL TT genotype
with high prevalence of diabetes would have biased the
HL genotype distribution due to premature death. There-
fore, a large-scale, prospective, longitudinal study with
detailed examinations on HDL and LDL particle compo-
sition and atherosclerosis status is required to completely
define the effect of the HL C-514T mutation on athero-
sclerotic vascular disease.
CONCLUSION
The TT genotype for the HL C-514T mutation is an
independent positive determinant of serum HDL choles-
terol levels and may serve as a protective factor against
vascular disease independent of traditional risk factors
in hemodialysis patients with supramedian CETP levels
(2.2 g/mL). These findings suggest the important in-
volvement of hepatic lipase on lipoprotein metabolism
and vascular disease in uremic patients with high CETP
status.
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